Your position:m.limatoxi.com>>EN>>EN>>Formulation>>Merck announces positive results from phase 2 KeyVibe-002 trial evaluating coformulation of vibostolimab pembrolizumab in previously treated patients with metastatic NSCLC>> article
Merck announces positive results from phase 2 KeyVibe-002 trial evaluating coformulation of vibostolimab pembrolizumab in previously treated patients with metastatic NSCLC
Editor:xuezhe Clicks:0Date:2023-12-8 14:56:51
Keyword:Merck
Healthoo Information:
Merck announces positive results from phase 2 KeyVibe-002 trial evaluating coformulation of vibostolimab pembrolizumab in previously treated patients with metastatic NSCLC
E-mail:xuezhe@healthoo.com
Tel.:86-10-68032463
Our services:
China Im\Ex data service
Service fees of Chinese Vision
Our service items
Online information introduction
Monthly information
Relative Information
  • Deqi Pharmaceutical Merck reached a global clinical cooperation
  • Merck to Acquire ADC Leader Seagen
  • Bayer, Merck Announced to Close Two Factories
  • Bayer, Merck Announced to Close Two Factories
  • Merck's clear vision in China
  • Merck Serono to set up new factory ...
  • Merck and Simcere launch JV in China
  • Merck and Simcere signed agreement to es...
  • Merck Serono to complete industry chain ...
  • Merck collaborates with Sinopharm to boost&nb...
    		•
    Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
    Tel:+86-10-68032463
    Baidu
    map